MDM2の小分子抗体によるp53経路のインビヴォ活性化

Lyubomir T Vassilev¹, Binh T Vu, Bradford Graves

¹Department of Discovery Oncology, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ 07110, USA. lyubomir.vassilev@roche.com

Science (New York, N.Y.)

|January 6, 2004

まとめ

研究者らは,MDM2を阻害する小分子,腫瘍で過剰発現しているタンパク質を特定した. この阻害はp53腫瘍抑制体を再活性化し,有望な新しいがん治療戦略を提供します.

科学分野:

腫瘍学腫瘍学
分子生物学は分子生物学である.
ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー

背景:

MDM2タンパク質の過剰発現はヒトの腫瘍に多く見られ,p53腫瘍抑制機能の低下につながる.
MDM2はp53の転写活動と安定性を否定的に調節し,腫瘍抑制作用を阻害する.
MDM2-p53の相互作用をターゲットにすることは,がん治療の潜在的な治療戦略です.

研究の目的:

MDM2.2の小分子アンタゴニストを特定し,特徴づけること.
これらのMDM2阻害剤の作用メカニズムを解明する.
臨床前がんモデルにおけるMDM2阻害の治療の可能性を評価する.

主な方法:

MDM2-p53結合インターフェイスをターゲットとする小分子抗生物質の特定.
MDM2阻害剤複合体の構造を決定するX線結晶学.
p53経路の活性化と抗腫瘍有効性を評価するためのインビトロおよびインビボ試験.

主要な成果:

MDM2.2の強力で選択的な小分子阻害剤の発見.
MDM2.2.のp53結合ポケット内の化合物結合の構造的確認
癌細胞におけるアポトーシスと細胞循環停止につながるp53経路の活性化を示す.
マウスモデルにおけるヒト腫瘍異種移植の成長の有意な阻害.

結論:

MDM2の小分子阻害は,がん治療の有効な戦略です.
これらの新しいアンタゴニストは,p53経路を効果的に再活性化し,抗腫瘍効果を誘発します.
MDM2阻害剤のさらなる開発は,腫瘍学における臨床応用に有望である.

さらに関連する動画

07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

関連する概念動画

01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...

02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

02:36

DNA Damage Can Stall the Cell Cycle

関連する実験動画